What Is the Apo B Blood Test and What Does It Show?

The apolipoprotein B (apo B) blood test measures the concentration of a protein called apolipoprotein B in your blood, and because every potentially artery-clogging lipoprotein particle carries exactly one copy of this protein, the test effectively counts the total number of those dangerous particles circulating in your bloodstream. That particle count turns out to be a stronger predictor of heart disease than the more familiar LDL cholesterol number on a standard lipid panel. Despite growing recognition of its value, the test remains dramatically underused: in 2019, only about 0.2% of adults in the United States had an apo B test drawn.¹

What ApoB Actually Is

Apolipoprotein B-100 is a large protein produced mainly by the liver. It wraps around fat-carrying particles in your blood, serving as a kind of structural shell that holds each particle together and allows it to interact with receptors on your cells. Every LDL particle has one apo B molecule on its surface. So does every VLDL (very low-density lipoprotein) particle and every IDL (intermediate-density lipoprotein) particle.² There is also a shorter version, apo B-48, produced in the intestine and found on chylomicrons (particles that carry fat absorbed from food), but the blood test focuses on apo B-100 because those are the particles that drive atherosclerosis.

Because the relationship is exactly one apo B molecule per particle, measuring apo B in your blood gives you a direct count of all atherogenic particles combined. A standard lipid panel, by contrast, estimates how much cholesterol is packed inside LDL particles. Those two numbers, particle count and cholesterol content, do not always agree, and when they diverge the particle count is the better guide to risk.

How ApoB Particles Damage Arteries

The connection between apo B particles and heart disease is not just statistical. The particles physically enter the walls of your arteries, get trapped there, and trigger the inflammatory cascade that builds plaque. The more apo B particles circulating in your blood, the more frequently they penetrate the artery lining and become stuck in the tissue underneath.³ Smaller, denser particles are especially problematic because they slip through the artery wall more easily and bind more tightly to structural molecules there.⁴

This is why the total number of particles matters so much. Two people can have the same LDL cholesterol level but very different numbers of particles. The person with more numerous, smaller particles has more apo B, more particles entering artery walls, and a higher risk of developing coronary heart disease. The cholesterol measurement alone misses this distinction.

Why ApoB Outperforms LDL Cholesterol

Your standard lipid panel reports LDL-C, which is the total mass of cholesterol riding inside LDL particles. The problem is that cholesterol content per particle varies widely from person to person. Some people carry large, cholesterol-rich LDL particles; others carry smaller particles with less cholesterol each. If you have many small particles, your LDL-C might look normal even though your arteries are being bombarded by a large fleet of atherogenic particles.

ApoB captures this hidden risk. A large analysis across multiple cohorts found that apo B consistently predicted new coronary heart disease after adjusting for standard risk factors, while the ratio of LDL-C to apo B, a measure of particle size, added little or no predictive value in most populations studied.⁵ In other words, it was the number of particles, not the cholesterol stuffed inside them, that predicted who actually had heart attacks. A detailed physiological review in the Journal of the American Heart Association laid out why this happens: the mechanisms governing how much cholesterol each particle carries are largely independent of the mechanisms determining how many particles exist, and it is the particle count that tracks with cardiovascular events.⁶

When ApoB and LDL Cholesterol Tell Different Stories

The technical term is “discordance,” and it is more common than you might expect. A person can have an LDL-C that looks reassuring while their apo B is quietly elevated. A systematic review examining people with metabolic syndrome or type 2 diabetes found this pattern repeatedly: patients achieved LDL-C targets yet still had high apo B levels, largely because their LDL particles were small and dense. The review concluded that relying on LDL-C alone underestimates cardiovascular risk in these groups.⁷

Discordance does not only matter in people with diabetes. The CARDIA study followed young adults for 25 years and found that those who had high apo B but low LDL-C were more likely to develop coronary artery calcification, an early marker of plaque buildup, compared to people whose numbers agreed.⁸ If those young adults had only been looking at LDL-C, they would have had no reason to worry.

ApoB Is Not Just Correlated With Heart Disease. It Likely Causes It.

Observational studies can show that two things travel together without proving one causes the other. Genetic studies help sort this out. A large Mendelian randomization analysis, which uses naturally occurring genetic differences as a kind of natural experiment, tested a wide range of lipid-related risk factors and ranked them by their causal contribution to coronary artery disease. ApoB came out on top. It was the only lipid measure consistently selected across all sensitivity analyses as a causal risk factor. No other cholesterol or triglyceride measurement made the cut.⁹

A separate Mendelian randomization study estimated the effect on lifespan itself. People genetically predisposed to higher apo B levels had measurably shorter-lived parents, and in the most fully adjusted analysis, the estimated effect was roughly two years of life lost per standard-deviation increase in genetically predicted apo B.¹⁰ Genetic evidence like this moves apo B from “useful biomarker” to “causal driver” in a way that standard cholesterol fractions have struggled to match.

What Your ApoB Number Means

Guidelines have been slower to set firm apo B targets than LDL-C targets. A 2024 review in Circulation noted that while clear LDL-C goals exist to trigger treatment changes, consistent apo B targets are still lacking across major guidelines.¹¹ That said, the general landscape is becoming clearer. European guidelines have suggested a target below 65 mg/dL for very-high-risk patients and below 80 mg/dL for high-risk patients. Canadian guidelines similarly endorse apo B measurement and provide treatment thresholds.

A large prospective study of people with hypertension found a U-shaped relationship between apo B levels and mortality: both all-cause and cardiovascular death risk were lowest around 100 mg/dL, rising when levels went much above or fell well below that mark.¹² The finding about very low levels is worth noting, though it may reflect the fact that extremely low apo B can signal underlying illness rather than good health. For most people focused on preventing cardiovascular disease, the practical concern is getting elevated apo B down, not worrying about it being too low.

Practical Details About Getting Tested

One practical advantage of the apo B test is that you do not need to fast for it. Standard LDL-C calculations can shift depending on whether you have recently eaten because triglycerides change after meals and feed into the formula used to estimate LDL-C. ApoB, being a direct measurement of a protein, is far less affected by recent food intake.¹³ This makes the test more convenient and arguably more reliable for routine screening.

The test itself uses an immunoturbidimetric assay, which is a standard automated lab method. An international reference material maintained by the IFCC and WHO ensures calibration across different lab vendors, and a new mass spectrometry reference method is expected to improve standardization further.¹⁴ In terms of cost, the test is inexpensive, typically running between $10 and $30 in the United States, though coverage varies by insurer. A cost-effectiveness analysis published in JAMA found that using an apo B goal for primary prevention statin therapy was cost-effective compared to alternative lipid goals, with the cost of the test itself being marginal relative to the overall expense of longer treatment.¹⁵

Who Benefits Most From ApoB Testing

The test is most informative when discordance between particle number and cholesterol content is likeliest. People with type 2 diabetes, insulin resistance, metabolic syndrome, or elevated triglycerides are the classic candidates, because these conditions tend to shift the LDL particle population toward smaller, denser forms that carry less cholesterol each. In these groups, LDL-C can look deceptively normal while the actual atherogenic particle load is elevated.⁷

Among people with type 2 diabetes specifically, one study found that the apo B to apo A1 ratio showed the strongest correlation with coronary heart disease risk, outperforming traditional LDL-C and even the non-HDL-C to HDL-C ratio.¹⁶ The picture is not entirely unanimous, though. An analysis from the FIELD study, a large trial involving people with type 2 diabetes, concluded that traditional lipid ratios performed about as well as apo B-based ratios for predicting cardiovascular events in that population.¹⁷ The disagreement likely reflects differences in study populations and which endpoints were measured, but it does caution against treating apo B as a magic bullet. It is better thought of as a sharper tool, especially useful when the standard panel leaves room for ambiguity.

People with a family history of early heart disease, those already on statins whose LDL-C is at goal but who continue to have cardiac events, and anyone whose lipid profile looks “off” (e.g. high triglycerides with seemingly normal LDL-C) are also good candidates. Young adults may benefit too, given the CARDIA findings that discordance in early adulthood predicted plaque decades later.⁸

The ApoB to ApoA1 Ratio

Some clinicians look beyond apo B alone and consider the ratio of apo B to apo A1, where apo A1 is the main protein on HDL (“good cholesterol”) particles. The idea is intuitive: a ratio captures the balance between atherogenic and protective particles in a single number. In overweight and obese individuals, this ratio has shown discriminatory ability for coronary heart disease, with a suggested cutoff around 0.80.¹⁸

A recent study found that the apo B to apo A1 ratio was the strongest independent lipid predictor of coronary heart disease overall, and it also predicted severe outcomes like heart attacks requiring intervention. The associations were strongest in men, people over 60, and those with hypertension, but weaker in patients with diabetes.¹⁹ The ratio’s weakness in diabetic patients aligns with the mixed findings from the FIELD trial mentioned earlier, suggesting that diabetes introduces metabolic complexity that no single lipid marker fully captures.

How to Lower Your ApoB

Statins remain the primary pharmacological tool for reducing apo B. They work by forcing the liver to pull more LDL particles out of the bloodstream, which naturally brings down the apo B count. Other medications like ezetimibe and PCSK9 inhibitors can be added if statins alone are not enough, and these also reduce apo B. In general, any therapy that lowers LDL particle number will lower apo B.

Lifestyle changes matter too, and in some ways apo B responds to lifestyle differently than LDL-C does. A year-long randomized study of overweight men found that exercise training significantly reduced apo B levels compared to controls, while LDL-C did not drop meaningfully. Changes in fitness tracked more closely with changes in apo B than with changes in LDL-C.²⁰ This is a striking result: if you only looked at LDL-C, you might conclude the exercise program was not affecting lipids. The apo B test told a different story.

Diet patterns also play a role. A population-based analysis found that people with elevated apo B, regardless of their LDL-C, tended to eat diets high in saturated fat and refined carbohydrates and low in vitamins and minerals, characteristic of a Western dietary pattern. Those with discordantly high apo B relative to their LDL-C had particularly low adherence to Mediterranean-style diets rich in fiber, unsaturated fats, and micronutrients.²¹ Shifting toward a more plant-forward, fiber-rich diet pattern is a reasonable step for someone looking to bring apo B down.

ApoB Beyond Heart Disease

The role of apo B is expanding beyond cardiology. A Mendelian randomization study published in Communications Biology found evidence that genetically elevated apo B shortens healthspan broadly and may increase risk for Alzheimer’s disease. The researchers noted that while apo B-containing lipoproteins normally cannot cross the blood-brain barrier, small amounts of apo B are expressed in brain tissue, suggesting a possible local mechanism.²²

A separate study in the Journal of the American Heart Association examined the relationship between apo B-to-LDL-C discordance and cognitive function more directly. People with higher apo B relative to their LDL-C scored lower on cognitive assessments, and part of this association was mediated by atherosclerotic plaque in the brain’s blood vessels.²³ The brain, like the heart, depends on healthy arteries, so it is not surprising that the same particle-driven plaque process could affect both organs.

ApoB also shows up in liver disease research. In people with hepatitis C infection, higher apo B levels were associated with substantially higher odds of fatty liver disease and more severe liver fat accumulation, even after adjusting for other metabolic factors.²⁴ Because apo B is assembled in the liver and is central to how the liver packages and exports fat, abnormal levels can reflect liver metabolic health as well as cardiovascular risk.

Rare Genetic Conditions Involving ApoB

At the extremes, mutations in the gene that codes for apo B can cause dramatic lipid abnormalities. Familial hypobetalipoproteinemia results from truncation mutations in the APOB gene, producing a shortened, dysfunctional protein. People with this condition have very low cholesterol levels and may develop fatty liver because the liver cannot properly export fat into the bloodstream. A more severe condition, abetalipoproteinemia, involves a different gene (MTP) that is needed for apo B-containing particles to be assembled at all. Both conditions are rare and are characterized by markedly low cholesterol.²⁵

On the other end, familial hypercholesterolemia involves defective LDL receptors that fail to clear apo B particles from the blood, leading to extremely high apo B and LDL-C from birth. In all of these genetic scenarios, apo B testing helps clarify the diagnosis and guides treatment decisions. The test can distinguish between conditions that raise cholesterol by producing too many particles versus those that raise cholesterol by making each particle larger and more cholesterol-rich, a distinction that standard lipid panels cannot reliably make on their own.

Why the Test Remains Uncommon

Given the evidence, you might expect apo B testing to be routine. It is not. In 2019, only about 0.21% of the U.S. population received an apo B test, compared to far higher rates for any component of a standard lipid panel. Testing was slightly more common among adults 65 and older, at 0.51%, versus 0.13% among younger adults.¹

Several factors explain this gap. LDL-C has decades of momentum in clinical guidelines, electronic health record templates, and physician training. Insurance coverage for apo B testing varies, and many primary care providers are simply not in the habit of ordering it. The lack of universally agreed-upon treatment targets, as noted by the Circulation review, also makes some clinicians hesitant to order a test they are unsure how to act on.¹¹ But the tide is shifting. Canadian, European, and some U.S. specialty guidelines now recommend apo B measurement in specific scenarios, and cost-effectiveness data increasingly supports broader use. If you are curious about your own apo B, the test is inexpensive and easy to request from your doctor, and the result can fill in a meaningful blind spot that a standard lipid panel leaves open.